Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

GSK Avandia/Insulin Use Based On 220-Patient Study Showing No Cardio Risk

  • News

Executive Summary

GlaxoSmithKline's long-awaited approval of Avandia in combination with insulin is based on a 220-patient study showing no cardiovascular safety signal in type 2 diabetes patients

You may also be interested in...



GSK Trial Registry Begins With Avandia; Includes 25 Unpublished Studies

GlaxoSmithKline's clinical trial registry for the diabetes drug Avandia includes five unpublished placebo-controlled trials

GSK Trial Registry Begins With Avandia; Includes 25 Unpublished Studies

GlaxoSmithKline's clinical trial registry for the diabetes drug Avandia includes five unpublished placebo-controlled trials

Avandia/Metformin Combo To Launch By End Of 2002, GSK Says

GlaxoSmithKline's Avandia/metformin combination diabetes product will be launched by the end of 2002, GSK Chief Operating Officer Bob Ingram told securities analysts

Table

View full table

Tags:
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS041352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By